within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AE04_Ziprasidone;

model Ziprasidone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 3.277777777777778e-05,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.0011,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011666666666666665,
    Tlag = 10.200000000000001,
    Vdp = 0.0072,
    k12 = 8.049999999999999e-05,
    k21 = 8.049999999999999e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ziprasidone</td></tr><tr><td>ATC code:</td><td>N05AE04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>118</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ziprasidone is an atypical antipsychotic medication primarily used for the treatment of schizophrenia and bipolar disorder in adults. It is approved for use and marketed under various brand names such as Geodon. Its mechanism of action involves antagonism at dopamine D2 and serotonin 5-HT2A receptors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Simon, N, et al., &amp; Azorin, JM (2022). Comorbidities and the right dose: antipsychotics. <i>Expert opinion on drug metabolism &amp; toxicology</i> 18(7-8) 507–518. DOI:<a href=\"https://doi.org/10.1080/17425255.2022.2113378\">10.1080/17425255.2022.2113378</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35979611/\">https://pubmed.ncbi.nlm.nih.gov/35979611</a></p></li><li><p>Crabtree, BL, &amp; Montgomery, J (2011). Iloperidone for the management of adults with schizophrenia. <i>Clinical therapeutics</i> 33(3) 330–345. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2011.03.006\">10.1016/j.clinthera.2011.03.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21600386/\">https://pubmed.ncbi.nlm.nih.gov/21600386</a></p></li><li><p>Potkin, SG, et al., &amp; McQuade, R (2013). Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. <i>Current medical research and opinion</i> 29(10) 1241–1251. DOI:<a href=\"https://doi.org/10.1185/03007995.2013.821973\">10.1185/03007995.2013.821973</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23822566/\">https://pubmed.ncbi.nlm.nih.gov/23822566</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AE04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ziprasidone;
